Rahul Kakkar

Entrepreneur Partner

Rahul joined Polaris Partners in 2021 and serves as an entrepreneur partner. He is a biotech executive and physician-scientist, founding and building biotechnology companies as well as working as a practicing physician.

Most recently, Rahul was Chief Executive Officer at Pandion Therapeutics, a company focused on therapeutics for autoimmune and inflammatory diseases, which he led from Series A through its clinical transition, initial public offering and its ultimate acquisition by Merck for $1.85B. Prior to joining Pandion, Rahul founded Corvidia Therapeutics, a precision cardiovascular company, where he served as Chief Medical Officer and Chief Strategy Officer. Corvidia Therapeutics was acquired by Novo Nordisk for $2.1B. Across his companies, Rahul has led fundraising totaling over $300M to date. Prior to Corvidia, Rahul served as a director in the Emerging Innovations Unit at AstraZeneca, where he was recognized with the AstraZeneca Leadership Recognition Award.

Rahul continues to practice cardiovascular medicine at the Brigham and Women’s Hospital in Boston, and is a lecturer in medicine at Harvard Medical School.

Rahul received his B.A. Cum Laude from Tufts University where he was a member of the Golden Key National Honor Society, and M.D. from the Tufts University School of Medicine, where he was the recipient of the Louis Weinstein Prize in Clinical Medicine and was inducted into the Alpha Omega Alpha Honor Society as a junior. He also served as an Albert Schweitzer Fellow.

This website is not an advertisement. This website is intended solely to provide general business information on Polaris Partners and any affiliates thereof (collectively, “Polaris”). Nothing on this website should be construed as an offer of investment advisory services by Polaris or a solicitation or an offer of interests in any Polaris fund. Visitors to this website are not to construe the contents of this website or any prior or subsequent communication from Polaris or any of its representatives, as legal, tax or investment advice. References to specific companies are for illustrative purposes only and do not represent all of the companies recommended for advisory clients. Such references are not intended to be, and should not be interpreted as, recommendations or investment advice. All information has been obtained from sources believed to be reliable, but its accuracy is not guaranteed, and Polaris disclaims any duty to update any of the information and data contained herein. Certain statements may be deemed forward-looking, but any such statements are not guarantees of any future performance and actual results or developments may differ materially from those discussed. There is no guarantee that investment objectives will be achieved or that any particular investment will be profitable. Past performance does not guarantee future results. Where applicable, figures include investments made directly and indirectly by the Polaris Main Funds and may include co-investments with the Polaris Growth Funds and the Polaris Innovation Funds. Please see the complete list of investments here, as well as the Terms of Use for additional information and disclosures.

 

The endorsements of current or past portfolio company executives are provided as illustrative examples and designed to demonstrate the benefits to portfolio companies of partnering with us. These statements are primarily aimed at prospective portfolio companies and not intended to solicit investors. The portfolio companies covered in these endorsements do not represent all portfolio company investments we have made. The experiences highlighted in these testimonials are solely those of the executives profiled and may not necessarily represent or be indicative of the current, past, or future experiences of other portfolio companies. Past results and experiences discussed are not indicative, or a guarantee of future results and experiences. We have not provided cash or other type of compensation in exchange for receiving these endorsements. We do not believe there are typically any material conflicts associated with providing these endorsements. The compensation of our portfolio company executives is primarily driven by the performance of their respective portfolio companies and any discretion we exercise in such compensation determinations is not influenced by whether an executive has provided a favorable statement. Additionally, the economic interests of our portfolio companies’ executives are generally well-aligned with ours and those of our investors. Nevertheless, the fact that these endorsements have been provided by individuals whose compensation we exercise a certain level of control over may incentivize them to provide favorable evaluations of their experiences working with us.